Treating some PD patients with a combination of LRRK2 inhibitors and GCase enhancers might be a viable approach given the finding that some idiopathic PD patients exhibit LRRK2 hyperactivity together with GCase hypoactivity [44, 82, 83, 101] (Fig. 1c). This evidence concerns the gene LRRK2 and Parkinson disease.